Digital Medicine System

DEVICE2 trials

Sponsors

Kishimoto Taishiro, Otsuka Pharmaceutical Development & Commercialization, Inc.

Conditions

First Episode PsychosisSchizoaffective DisorderSchizophreniaSchizophrenia, schizoaffective disorder Schizophrenia

Phase 2

Exploratory Research to Assess Usability of the Digital Medicine System in Patients with Schizophrenia or Schizoaffective Disorder

Active, not recruitingJPRN-jRCTs032190089

Kishimoto TaishiroSchizophrenia, schizoaffective disorder Schizophrenia

Start: 2020-09-16Target: 30Updated: 2026-06-29

Phase 4

A Trial to Explore Acceptance and Performance of Using a Digital Medicine System With Healthcare Professionals and Adults With Schizophrenia, Schizoaffective Disorder, or First Episode Psychosis on an Oral Atypical Antipsychotic

CompletedNCT03568500

Otsuka Pharmaceutical Development & Commercialization, Inc.First Episode Psychosis, Schizoaffective Disorder, Schizophrenia

Start: 2018-05-21End: 2019-09-06Updated: 2020-07-16

Related Papers

Safety Evaluation in Iterative Development of Wearable Patches for Aripiprazole Tablets With Sensor: Pooled Analysis of Clinical Trials

JMIR Formative Research2023-09-232 citations

Hummingbird Study: Results from an Exploratory Trial Assessing the Performance and Acceptance of a Digital Medicine System in Adults with Schizophrenia, Schizoaffective Disorder, or First-Episode Psychosis.

2021-02-1212 citations

T96. RESULTS OF THE HUMMINGBIRD STUDY A MULTICENTRE, PRAGMATIC TRIAL OF A DIGITAL MEDICINE SYSTEM

Schizophrenia Bulletin2020-04-011 citations

Hummingbird Study: a study protocol for a multicentre exploratory trial to assess the acceptance and performance of a digital medicine system in adults with schizophrenia, schizoaffective disorder or first-episode psychosis

BMJ Open2019-06-0117 citations